#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13904	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2322	731.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1561	1561	C	871	C,A	870,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23402	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3777	769.3	0	.	n	.	0	T695C	SNP	695	695	T	1132	1132	C	890	C,T,G,A	884,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23402	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3777	769.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	2075	2075	G	898	G,T,C,A	893,3,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23402	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3777	769.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2408	2408	C	806	C,G	805,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23402	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3777	769.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2482	2482	A	771	A	771	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23402	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3777	769.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3034	3034	C	888	C,T	885,3	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2016	folP	855	855	100.0	folP.l15.c4.ctg.1	2102	119.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1304	1306	AGC	207;209;210	A;G;C,G	207;209;209,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4826	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	4000	150.6	1	SNP	p	S91F	1	.	.	271	273	TTC	923	925	TTC	176;177;178	T,A;T,G;C	175,1;176,1;178	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4826	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	4000	150.6	1	SNP	p	D95G	1	.	.	283	285	GGC	935	937	GGC	177;176;174	G;G;C	177;176;174	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4826	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	4000	150.6	1	SNP	p	G95N	0	.	.	283	285	GGC	935	937	GGC	177;176;174	G;G;C	177;176;174	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1746	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1757	124.0	0	.	p	.	0	F184L	NONSYN	550	552	TTC	1091	1093	TTG	189;189;189	T;T,A;G	189;188,1;189	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1746	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1757	124.0	1	SNP	p	G45D	0	.	.	133	135	GGC	674	676	GGC	231;234;235	G;G;C,A	231;234;234,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1024	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1468	87.2	0	.	n	.	0	A197.	DEL	197	197	A	878	878	A	193	A	193	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4714	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3440	170.6	1	SNP	p	D86N	0	.	.	256	258	GAC	867	869	GAC	213;212;211	G;A,G;C	213;211,1;211	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4714	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3440	170.6	1	SNP	p	R87W	0	.	.	259	261	CGT	870	872	CGT	213;213;215	C,A,T;G;T	210,2,1;213;215	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4714	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3440	170.6	1	SNP	p	S87R	1	.	.	259	261	CGT	870	872	CGT	213;213;215	C,A,T;G;T	210,2,1;213;215	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4714	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3440	170.6	1	SNP	p	R87I	0	.	.	259	261	CGT	870	872	CGT	213;213;215	C,A,T;G;T	210,2,1;213;215	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4714	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3440	170.6	1	SNP	p	S88P	0	.	.	262	264	TCC	873	875	TCC	213;212;212	T,C;C,A;C	212,1;211,1;212	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3908	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3014	161.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1698	1700	GGC	190;189;189	G;G;C	190;189;189	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1446	1448	GCA	183;181;182	G;C,A;A	183;180,1;182	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1449	1451	ATC	183;181;181	A;T,G;C,A	183;180,1;180,1	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1461	1463	GTG	178;180;181	G,T;T,G,A;G,T	177,1;178,1,1;180,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1461	1463	GTG	178;180;181	G,T;T,G,A;G,T	177,1;178,1,1;180,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1965	1967	ACC	212;211;212	A;C;C	212;211;212	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2019	2021	GCG	206;204;207	G;C,T;G,T	206;203,1;206,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2019	2021	GCG	206;204;207	G;C,T;G,T	206;203,1;206,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2142	2144	AGC	202;201;202	A,G;G,T,C;C	201,1;199,1,1;202	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2151	2153	GGC	211;210;211	G,C;G;C,T,G	210,1;210;209,1,1	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3632	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2888	156.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2169	2171	CCG	212;210;209	C,T,A;C,T,G;G,C,A	209,1,2;208,1,1;206,2,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5058	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3578	176.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1832	1834	CCG	199;199;194	C;C,G;G,C	199;198,1;193,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2236	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2276	122.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	829	829	C	164	C	164	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	100	94.0	porB1a.l6.c17.ctg.2	177	54.3	0	.	p	.	0	M18T	NONSYN	52	54	ATG	128	130	ACG	60;58;55	A;C;G	60;58;55	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	100	94.0	porB1a.l6.c17.ctg.2	177	54.3	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	170	172	CAA	23;21;20	C;A;A	23;21;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	150	92.67	porB1a.l6.c17.ctg.3	152	36.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	18;19;23	T;T;A	18;19;23	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	150	92.67	porB1a.l6.c17.ctg.3	152	36.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	45;45;45	C;A;T	45;45;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	150	92.67	porB1a.l6.c17.ctg.3	152	36.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	45;45;45	A;G;T	45;45;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	150	92.67	porB1a.l6.c17.ctg.3	152	36.8	0	.	p	.	0	A275V	NONSYN	823	825	GCA	65	67	GTA	45;45;45	G;T;A	45;45;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	272	porB1a	984	150	92.67	porB1a.l6.c17.ctg.3	152	36.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	45;45;45	T,C;A;C	44,1;45;45	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	587	589	GAA	250;249;248	G;A;A,C	250;249;247,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	875	877	GAT	245;244;243	G,C;A,C;T,G	244,1;243,1;242,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	998	1000	TCA	260;259;260	T;C;A	260;259;260	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1127	1129	GTC	294;292;292	G,A;T,G;C,T	293,1;291,1;290,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1139	1141	TCT	280;277;277	T;C;T	280;277;277	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	A296V	NONSYN	886	888	GCA	1361	1363	GTA	225;224;226	G;T,G;A,C	225;223,1;225,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1457	1459	GCA	281;282;283	G;C,A;A,G	281;281,1;282,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	1	SNP	p	G120K	1	.	.	358	360	AAG	833	835	AAG	243;244;245	A;A;G,T,A	243;244;243,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	1	SNP	p	D121N	0	.	.	361	363	GAC	836	838	GAC	245;243;240	G;A;C	245;243;240	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2936	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1662	214.2	1	SNP	p	A121D	1	.	.	361	363	GAC	836	838	GAC	245;243;240	G;A;C	245;243;240	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9548	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5163	230.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1398	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1385	125.4	1	SNP	p	V57M	1	.	.	169	171	ATG	696	698	ATG	251;250;248	A;T;G	251;250;248	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
